Alzamend Neuro, Inc.
ALZN
$2.77
-$0.19-6.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 54.61% | 65.92% | 61.07% | 51.89% | 33.14% |
| Total Depreciation and Amortization | 0.00% | 17.05% | 41.11% | 77.62% | 120.87% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -65.02% | -75.45% | -83.61% | -78.04% | -73.31% |
| Change in Net Operating Assets | -463.61% | -281.02% | -169.73% | -75.16% | -71.46% |
| Cash from Operations | 20.58% | 19.52% | 10.61% | 37.76% | 7.32% |
| Capital Expenditure | -103.80% | 38.86% | 38.86% | 38.86% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -103.80% | 38.86% | 38.86% | 38.86% | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 115.94% | 117.01% | 13,061.75% | 626,150.00% | 626,150.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 268.39% | 599.01% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 185.85% | 390.97% | 64,912.02% | 2,807,950.00% | 1,826,150.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 174.98% | 143.36% | 143.34% | 94.90% | 46.60% |